MedTrace Logo

Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

NCT04061863 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-08

No results posted yet for this study

Summary

Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to antigen-presenting cells. Therefore, combining immunotherapy (Nivolumab) with chemotherapy (Eribulin) is a promising anti-cancer strategy.

Conditions

Interventions

DRUG

Nivolumab

Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Korean Cancer Study Group (KCSG)

    collaborator UNKNOWN

  • Eisai Korea Inc.

    collaborator INDUSTRY

  • Ono pharmaceutical Korea

    collaborator UNKNOWN

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • JEEHYUN KIM, MD,PhD · Seoul National University Bundang Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2022-04-30
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04061863 on ClinicalTrials.gov